Share on LinkedInShare on LinkedIn

ARTICLE · 04 MARCH 1999

Merger between Astra (Sweden) and Zeneca (UK) approved by the Commission under certain conditions

Sundström Rieser & Cie/Nordic Law Offices
Explore more from Sundström Rieser & Cie/Nordic Law Offices

BelgiumAntitrust/Competition Law
The new concentration will have the name of AstraZenca and the management will be held equally by both parties.
However this merger has been possible only by divestiture commitments.

The background.

Astra and Zeneca are both active in the research, production and sales of pharmaceutical products. Astra manufacturers also certain medical devices, Zeneca has on its part a major agriculture chemicals and speciality chemicals business.
The new company will be held 46,5% by Astra and 53,5% by Zeneca.

The overlaps between the parties were mainly observed in the anti-hypertension drugs, anaesthetics and anti-asthmatics. For this reason the Commission raised serious doubts with regard to plain and combined beta-blockers and local anaesthetics where the parties' shares attained more than 50%.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from